About
Rajeev Dadoo is COO and Managing Partner of SR One, which he joined in 2004, and is an alum of the Kauffman Fellows Program. He invests in therapeutics and healthcare-technology companies, drawing on prior roles in GSK's Competitive Excellence group, technology and clinical development at Genentech, and product and business development positions at Bio-Rad Laboratories and Genome Therapeutics; he also co-founded Unimicro Technologies. He holds a BA in Chemistry and Mathematics from Knox College, a PhD in Chemistry from Stanford University, and an MBA from the Wharton School.
Invests in
BiotechDigital HealthHealthtech
Experience
- SR OneManaging Partnercurrent2004 — present
Education
- Stanford UniversityPhD, Chemistry
- Knox CollegeBA
- The Wharton School/Univ. PennMBA
Same school
Also attended Stanford University1,575
+ 1,569 more
Deals · 4
Dren BioBoard seat
via SR One Capital Management · filed Mar 2022 · $80M raise
ARS PharmaceuticalsBoard seat
via SR One Capital Management · filed Sep 2021 · $55M raise
Palleon PharmaceuticalsBoard seat
via SR One Capital Management · filed Sep 2020 · $100M raise
Navitor PharmaceuticalsBoard seat
via SR One Capital Management · filed May 2020 · $20.2M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at SR One Capital Management
Network2
Investors connected to Rajeev in public investor directories — a warm-intro map.